Magnesium Sulfate Has No Role in Acute Ischemic Stroke or Aneurysmal Subarachnoid Hemorrhage
Routine use of intravenous magnesium sulfate is not recommended for either acute ischemic stroke or aneurysmal subarachnoid hemorrhage, as it provides no benefit in reducing mortality, disability, or delayed cerebral ischemia. 1, 2
Aneurysmal Subarachnoid Hemorrhage (aSAH)
The 2023 AHA/ASA guidelines explicitly state that routine use of intravenous magnesium is not recommended for patients with aSAH 1. This recommendation is based on:
- No improvement in neurological outcomes: Multiple randomized controlled trials and meta-analyses demonstrated that magnesium sulfate does not reduce cerebral infarction or mortality 1
- No reduction in delayed cerebral ischemia (DCI): Despite preclinical data suggesting magnesium could improve cerebral blood flow and decrease vasospasm, clinical evidence found no benefit 1
- Ineffective CSF penetration: Some have argued that CSF magnesium concentration matters more than peripheral levels, but this remains unvalidated 1
Contradictory Evidence Worth Noting
While the guidelines are clear, some older studies showed conflicting results:
- A 2010 German RCT 3 found significantly lower delayed ischemic infarction rates (22% vs 51%, p=0.002) with high-dose IV magnesium targeting serum levels of 2.0-2.5 mmol/L
- A 2011 meta-analysis 4 suggested decreased risk of poor outcome (RR 0.78,95% CI 0.66-0.93)
However, the larger, more recent IMASH trial 5 with 327 patients found no difference in outcomes (64% favorable outcome in magnesium group vs 63% in placebo), and an individual patient data meta-analysis 6 of 1,981 patients confirmed no benefit regardless of timing of administration.
The guideline recommendation supersedes these older, smaller studies and should guide practice.
Acute Ischemic Stroke (AIS)
The 2018 AHA/ASA guidelines state that neuroprotective agents including magnesium are not recommended for AIS treatment 2. Key evidence:
- FAST-MAG trial failure: This landmark trial tested hyperacute magnesium infusion starting during ambulance transport and found no differences between magnesium and placebo 2
- Cochrane review confirmation: Systematic review of neuroprotection trials confirmed no benefit 2
Single Contradictory Study
One 2013 Iranian study 7 of 107 patients showed significant recovery with magnesium (4g bolus + 16g over 24 hours) compared to placebo. This single positive study is vastly outweighed by the negative FAST-MAG trial and guideline recommendations, and should not change practice.
FDA-Approved Indications
Magnesium sulfate IV is FDA-approved for 8:
- Magnesium deficiency/hypomagnesemia
- Total parenteral nutrition supplementation
- Pre-eclampsia and eclampsia seizure prevention and control
Stroke is not an FDA-approved indication.
Future Directions
A 2025 review 9 suggests potential for intra-arterial magnesium administration during mechanical thrombectomy to deliver high concentrations directly to ischemic tissue while avoiding systemic exposure limitations. This remains investigational and should only be used in clinical trials.
Clinical Bottom Line
- Do not administer magnesium sulfate for neuroprotection in acute ischemic stroke
- Do not administer magnesium sulfate to prevent delayed cerebral ischemia in subarachnoid hemorrhage
- Do use nimodipine (not magnesium) for aSAH patients to prevent DCI and improve outcomes 1
- Do correct actual hypomagnesemia if present, as this is a legitimate indication 8
The evidence is clear and consistent across the highest quality guidelines: magnesium sulfate has no role in stroke management beyond correcting documented deficiency states.